TheraRadar

SecuraBio

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 5/19/2025

23
Total Trials
5
Phase 3
10
Phase 2
1
Recruiting
185
Score

Pipeline by Phase

Phase 3
5
Phase 2
10
Phase 1
10

Therapeutic Focus

Small Lymphocytic Lymphoma Healthy Chronic Lymphocytic Leukemia Lymphoma Indolent Non-Hodgkin Lymphoma

Clinical Trials (23)

NCT06522737 Phase 3 RECRUITING

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Started: 5/19/2025

NCT02204982 Phase 3 TERMINATED

Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma

Started: 9/1/2014

NCT02049515 Phase 3 COMPLETED

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

Started: 12/1/2013

NCT02004522 Phase 3 COMPLETED

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

Started: 11/1/2013

NCT02576275 Phase 3 WITHDRAWN

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

Started: 12/1/2015

NCT03372057 Phase 2 COMPLETED

A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Started: 2/22/2018

NCT04038359 Phase 2 COMPLETED

A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma

Started: 9/24/2019

NCT02711852 Phase 2 COMPLETED

A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)

Started: 4/1/2016

NCT01882803 Phase 2 COMPLETED

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

Started: 6/17/2013

NCT03370185 Phase 2 WITHDRAWN

Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Started: 2/12/2018

NCT02605694 Phase 2 WITHDRAWN

Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Started: 12/1/2015

NCT01851707 Phase 2 COMPLETED

A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone

Started: 4/1/2013

NCT01653756 Phase 2 COMPLETED

A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects

Started: 7/1/2012

NCT02391545 Phase 1 TERMINATED

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Started: 12/1/2014

NCT04193293 Phase 1 TERMINATED

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Started: 6/1/2020

NCT02292225 Phase 1 TERMINATED

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

Started: 2/1/2015

NCT01549106 Phase 1 COMPLETED

IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study

Started: 8/1/2011

NCT01925911 Phase 1 COMPLETED

Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam

Started: 8/1/2013

NCT01476657 Phase 1 TERMINATED

A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies

Started: 10/1/2011

NCT01947777 Phase 1 COMPLETED

Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145

Started: 10/1/2013

NCT02095587 Phase 1 COMPLETED

Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects

Started: 3/1/2014

NCT02307461 Phase 1 COMPLETED

Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145

Started: 11/1/2014

NCT01836861 Phase 1 COMPLETED

IPI-145 ADME and Absolute Bioavailability Study

Started: 3/1/2013

Drug Candidates

Duvelisib IPI-145 IPI-145 (duvelisib) IPI-145, a PI3K Inhibitor
Activity Status: Slowing
Last Trial Started: 5/19/2025
Last Trial Ended: 12/22/2023
Trials (12 months): 0
Completed Trials: 14
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.